Concepts (111)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Photosensitizing Agents | 7 | 2018 | 23 | 3.630 |
Why?
|
| Photochemotherapy | 7 | 2018 | 21 | 3.320 |
Why?
|
| Neoplasms | 6 | 2022 | 692 | 2.140 |
Why?
|
| Drug Delivery Systems | 4 | 2018 | 104 | 1.590 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2018 | 104 | 1.520 |
Why?
|
| Oligonucleotides, Antisense | 5 | 2015 | 30 | 1.360 |
Why?
|
| Nanoparticles | 2 | 2022 | 52 | 1.350 |
Why?
|
| Cell Line, Tumor | 11 | 2022 | 725 | 1.220 |
Why?
|
| Oligonucleotides | 4 | 2018 | 30 | 1.190 |
Why?
|
| Albumins | 2 | 2017 | 45 | 1.040 |
Why?
|
| Dendrimers | 2 | 2015 | 3 | 1.030 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 607 | 0.890 |
Why?
|
| Drug Carriers | 2 | 2015 | 21 | 0.890 |
Why?
|
| Endocytosis | 3 | 2015 | 10 | 0.880 |
Why?
|
| Mice | 9 | 2022 | 2476 | 0.850 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2018 | 14 | 0.650 |
Why?
|
| Immunoconjugates | 1 | 2018 | 9 | 0.640 |
Why?
|
| Antibodies | 1 | 2018 | 52 | 0.640 |
Why?
|
| Nanotubes, Carbon | 1 | 2018 | 23 | 0.630 |
Why?
|
| Animals | 10 | 2022 | 7450 | 0.620 |
Why?
|
| Transfection | 3 | 2015 | 191 | 0.610 |
Why?
|
| Molecular Probes | 1 | 2017 | 16 | 0.600 |
Why?
|
| Mice, Nude | 4 | 2018 | 290 | 0.590 |
Why?
|
| Molecular Imaging | 1 | 2017 | 20 | 0.590 |
Why?
|
| Radiopharmaceuticals | 1 | 2017 | 90 | 0.570 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 148 | 0.550 |
Why?
|
| Positron-Emission Tomography | 1 | 2017 | 163 | 0.550 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 244 | 0.510 |
Why?
|
| Light | 1 | 2015 | 24 | 0.510 |
Why?
|
| Polyethylene Glycols | 3 | 2018 | 64 | 0.480 |
Why?
|
| Spheroids, Cellular | 3 | 2018 | 37 | 0.480 |
Why?
|
| Mice, Inbred BALB C | 3 | 2018 | 168 | 0.470 |
Why?
|
| Humans | 18 | 2022 | 31836 | 0.430 |
Why?
|
| Tissue Distribution | 3 | 2018 | 60 | 0.420 |
Why?
|
| Polyethyleneimine | 1 | 2011 | 2 | 0.390 |
Why?
|
| Lipids | 2 | 2012 | 228 | 0.370 |
Why?
|
| Receptors, Bombesin | 1 | 2010 | 3 | 0.370 |
Why?
|
| Drug Resistance, Multiple | 2 | 2018 | 9 | 0.330 |
Why?
|
| 3T3 Cells | 2 | 2018 | 14 | 0.320 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 114 | 0.300 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 564 | 0.280 |
Why?
|
| Oligopeptides | 2 | 2018 | 45 | 0.270 |
Why?
|
| Microscopy, Confocal | 2 | 2015 | 65 | 0.250 |
Why?
|
| Apoptosis | 2 | 2018 | 354 | 0.250 |
Why?
|
| Cell Line | 2 | 2018 | 434 | 0.240 |
Why?
|
| Postural Balance | 1 | 2016 | 182 | 0.230 |
Why?
|
| Pesticides | 1 | 2016 | 200 | 0.220 |
Why?
|
| Occupational Exposure | 1 | 2016 | 233 | 0.220 |
Why?
|
| Transients and Migrants | 1 | 2016 | 291 | 0.210 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 245 | 0.210 |
Why?
|
| Esters | 1 | 2022 | 10 | 0.210 |
Why?
|
| Adenosine Triphosphate | 1 | 2022 | 53 | 0.210 |
Why?
|
| Adenosine | 1 | 2022 | 59 | 0.200 |
Why?
|
| Female | 5 | 2018 | 19859 | 0.200 |
Why?
|
| Reactive Oxygen Species | 1 | 2022 | 156 | 0.200 |
Why?
|
| Hispanic Americans | 1 | 2016 | 942 | 0.170 |
Why?
|
| Nanomedicine | 1 | 2018 | 16 | 0.160 |
Why?
|
| Infrared Rays | 1 | 2018 | 18 | 0.160 |
Why?
|
| Phospholipids | 1 | 2018 | 28 | 0.160 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2018 | 22 | 0.160 |
Why?
|
| Doxorubicin | 1 | 2018 | 82 | 0.160 |
Why?
|
| Pyrazines | 1 | 2018 | 13 | 0.160 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2018 | 58 | 0.160 |
Why?
|
| Flow Cytometry | 1 | 2018 | 184 | 0.150 |
Why?
|
| Recombinant Proteins | 1 | 2018 | 247 | 0.150 |
Why?
|
| Pyridines | 1 | 2018 | 76 | 0.150 |
Why?
|
| Cell Survival | 1 | 2018 | 286 | 0.150 |
Why?
|
| Copper Radioisotopes | 1 | 2017 | 3 | 0.150 |
Why?
|
| Heterocyclic Compounds, 1-Ring | 1 | 2017 | 3 | 0.150 |
Why?
|
| Hybridomas | 1 | 2017 | 4 | 0.150 |
Why?
|
| Chelating Agents | 1 | 2017 | 17 | 0.150 |
Why?
|
| Organometallic Compounds | 1 | 2017 | 23 | 0.150 |
Why?
|
| Biological Transport | 2 | 2015 | 69 | 0.150 |
Why?
|
| Ligands | 2 | 2015 | 80 | 0.150 |
Why?
|
| Indoles | 1 | 2017 | 56 | 0.150 |
Why?
|
| Base Sequence | 2 | 2015 | 251 | 0.150 |
Why?
|
| Hela Cells | 2 | 2018 | 78 | 0.130 |
Why?
|
| NIH 3T3 Cells | 1 | 2015 | 43 | 0.130 |
Why?
|
| Receptors, Cell Surface | 1 | 2015 | 70 | 0.120 |
Why?
|
| Protein Binding | 1 | 2015 | 201 | 0.120 |
Why?
|
| Infant Food | 1 | 2014 | 3 | 0.120 |
Why?
|
| Silicon Dioxide | 1 | 2014 | 9 | 0.120 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2014 | 12 | 0.120 |
Why?
|
| Chromatography, Affinity | 1 | 2014 | 15 | 0.120 |
Why?
|
| Caveolins | 1 | 2011 | 2 | 0.100 |
Why?
|
| Cations | 1 | 2011 | 10 | 0.100 |
Why?
|
| Intracellular Space | 1 | 2010 | 16 | 0.090 |
Why?
|
| Luciferases, Firefly | 1 | 2010 | 3 | 0.090 |
Why?
|
| Kinetics | 1 | 2010 | 209 | 0.090 |
Why?
|
| Case-Control Studies | 1 | 2016 | 895 | 0.060 |
Why?
|
| North Carolina | 1 | 2016 | 1514 | 0.050 |
Why?
|
| Intracellular Membranes | 1 | 2018 | 9 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2018 | 80 | 0.040 |
Why?
|
| Reagent Strips | 1 | 2014 | 4 | 0.030 |
Why?
|
| Powders | 1 | 2014 | 8 | 0.030 |
Why?
|
| DNA Probes | 1 | 2014 | 19 | 0.030 |
Why?
|
| Infant Formula | 1 | 2014 | 11 | 0.030 |
Why?
|
| Equipment Design | 1 | 2014 | 172 | 0.030 |
Why?
|
| Adult | 1 | 2016 | 9327 | 0.030 |
Why?
|
| Aged | 1 | 2016 | 10288 | 0.030 |
Why?
|
| Carbohydrates | 1 | 2012 | 8 | 0.030 |
Why?
|
| Nucleic Acids | 1 | 2012 | 6 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2012 | 114 | 0.020 |
Why?
|
| Middle Aged | 1 | 2016 | 11824 | 0.020 |
Why?
|
| Peptides | 1 | 2012 | 119 | 0.020 |
Why?
|
| Infant | 1 | 2014 | 1055 | 0.020 |
Why?
|
| Receptors, sigma | 1 | 2010 | 3 | 0.020 |
Why?
|
| Amides | 1 | 2010 | 18 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2012 | 508 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2012 | 180 | 0.020 |
Why?
|
| Male | 1 | 2016 | 19091 | 0.020 |
Why?
|